Evidence Guide · Data at a Glance

Clinical Evidence
at a Glance

A visual reference to the published outcomes behind implant-based breast reconstruction — complication rates, implant loss, capsular contracture and the size of the evidence base. Every figure is sourced from a peer-reviewed study, with its citation shown alongside.

7 min read 📅 Last reviewed: 2026-07-21 Advanced Biomedical Concept Medical Team

How to Read This Page

⚠ Important — different studies, not a head-to-head trial

The figures below come from separate published studies with different patient cohorts, complication definitions, follow-up periods and surgical settings. They are presented together to give indicative context — not as a controlled head-to-head comparison. A lower number in one study does not, on its own, prove one material or technique is superior to another.

Each bar is labelled with its own source. Where a figure is a device-specific ABC-related series it is marked as such. Always read outcomes in the context of the full publication and your own clinical judgement.

This page gathers the published outcome data that appears across ABC's clinical guides into one visual reference. It is intended for surgeons and informed readers who want the numbers and their sources in one place. Full narrative context lives in the prepectoral breast reconstruction and biological matrix pillar guides, and a structured material comparison lives in biological matrix vs. ADM.

Overall Complication Rates

Reported overall or major-complication rates in implant-based reconstruction series. Ranges reflect pooled meta-analyses; single values reflect individual cohorts.

Reported complication rate · lower is better
Complication Rates by Series

Scale 0–35%. Definitions of "complication" differ between studies.

Bovine pericardium (prepectoral DTI)De Vita 2024 · n=65 · major complications
9.2%
ADM (meta-analysis range)Zhu & Liu 2023 · n=2,667 · ~15–30%
15–30%
Synthetic mesh (randomised)Gschwantler-Kaulich 2016 · ~31%
~31%
0%17.5%35%

Read with care: the ADM figure is a pooled range across 2,667 patients; the bovine-pericardium figure is a single 65-patient prepectoral DTI cohort. Cohort size and case mix differ substantially.

Implant Loss / Explantation

Implant loss (device removal) is one of the most consistently reported and clinically meaningful endpoints in reconstruction outcomes.

Implant loss rate · lower is better
Implant Loss by Series

Scale 0–10%.

Bovine pericardium (ExaShape series)Mazzocchi 2022 · n=21 · 1 implant loss
4.8%
ADM (iBAG registry)Masià 2020 · n=1,450 procedures
6.5%
0%5%10%

Read with care: the ExaShape figure is a single loss in a small 21-patient early series — a wide confidence interval. The iBAG figure is a large real-world registry. Small denominators make single-patient events swing the percentage sharply.

Capsular Contracture

Capsular contracture (Baker grade III–IV, unless noted) is a longer-term outcome; reported rates depend heavily on follow-up length and grading.

Capsular contracture rate · lower is better
Capsular Contracture by Series

Scale 0–15%. Grading systems and follow-up differ.

ADM (iBAG registry)Masià 2020 · n=1,450 · ~2.1%
2.1%
Prepectoral (Nogueira Sixto 2025)n=112 · ~2.7%
2.7%
0%7.5%15%

Read with care: capsular contracture accrues over years, so rates in shorter-follow-up series read lower. Prepectoral placement in general has been associated with low contracture rates in the literature[5], but grading and follow-up are not standardised across these studies.

Size of the Evidence Base

How many patients sit behind each source. Larger denominators generally give more stable, generalisable estimates — a key reason registry and meta-analytic data carry weight even when device-specific series are smaller.

Patients / procedures analysed · larger is more robust
Cohort Sizes Across Cited Sources

Scale 0–2,800 patients.

ADM meta-analysisZhu & Liu 2023
2,667
iBAG prepectoral registryMasià 2020
1,450
Bovine pericardium DTI cohortDe Vita 2024
65
ExaShape early seriesMazzocchi 2022
21
01,4002,800

Why this matters: bovine-pericardium biological matrix is a newer material, so its device-specific evidence base is smaller and growing. Larger ADM datasets reflect a longer market history — not necessarily a better outcome. Interpreting small series requires caution around confidence intervals.

Evidence Timeline

Key publications that shaped the modern prepectoral, biological-matrix and fat-grafting approach — the studies cited throughout ABC's guides.

Interpreting the Data Responsibly

Three principles apply to every figure on this page. First, denominators matter: a 4.8% loss rate from a 21-patient series carries a much wider confidence interval than a 6.5% rate from 1,450 procedures. Second, definitions vary: "complication" and capsular-contracture grading are not standardised across studies, so identical labels can measure different things. Third, time matters: outcomes like capsular contracture accrue over years, so shorter-follow-up series naturally read lower.

Bovine-pericardium biological matrix is a newer material with a smaller but growing device-specific evidence base. The available series are encouraging, but they are early and small relative to the large ADM datasets accumulated over a longer market history. The honest reading is that the data is indicative and promising, not yet definitive — and that is exactly how it should be presented to patients and colleagues. For the full narrative and material-by-material discussion, see the biological matrix vs. ADM comparison and the prepectoral reconstruction pillar.

Advanced Biomedical Concept · Evidence Library
The Studies Behind ABC's Platform

ExaShape and PREPEC bovine-pericardium biological matrix and the EXAFAT fat-grafting system are supported by a growing body of peer-reviewed evidence. Explore the full clinical library, device IFUs and surgical technique resources.

Frequently Asked Questions

Can I compare these numbers directly to choose a material?
No. The figures come from separate studies with different cohorts, definitions and follow-up. They give indicative context, not a controlled head-to-head result. A material decision should rest on the full evidence, device indications and your clinical judgement — not a single bar on a chart.
Why is the bovine-pericardium evidence base smaller?
Bovine-pericardium biological matrix is a newer material than acellular dermal matrix, so its device-specific series are more recent and smaller. The evidence is growing, but large registries and meta-analyses have naturally accumulated more patients over a longer market history.
Why does a small series show a higher implant-loss percentage?
With small denominators, a single event moves the percentage sharply — one implant loss in 21 patients is 4.8%, while the same event in 1,450 procedures would be under 0.1%. Small early series therefore carry wide confidence intervals and should be read with caution.
Are these figures a claim about ABC device performance?
No. This page is an educational summary of published literature. It is not a promotional performance claim, not a substitute for the device Instructions for Use, and not clinical advice. Device-specific outcomes should always be read from the primary publications and IFU.
Where can I read the full context behind these numbers?
The narrative context lives in ABC's pillar guides: prepectoral breast reconstruction, biological matrix for breast reconstruction, and the biological matrix vs. ADM comparison, plus the fat dialysis guide for the fat-grafting evidence.

References

  1. De Vita R, et al. "Prepectoral direct-to-implant breast reconstruction with acellular bovine pericardium matrix." Clin Breast Cancer. 2024. DOI: 10.1016/j.clbc.2024.06.004. (Prepectoral DTI series, n=65 — 9.2% major complications)
  2. Zhu L, Liu P. "Acellular dermal matrix in implant-based breast reconstruction: a meta-analysis." Aesthetic Plast Surg. 2023. DOI: 10.1007/s00266-023-03296-0. (ADM meta-analysis, n=2,667)
  3. Masià J, et al. "The iBAG multicentre study of prepectoral ADM reconstruction." J Surg Oncol. 2020. DOI: 10.1002/jso.26073. (Real-world registry, 1,450 procedures / 30 centres)
  4. Casella D, et al. "STEP: bovine pericardium in prepectoral reconstruction." J Clin Med. 2025. DOI: 10.3390/jcm14176296. (Device-specific safety series)
  5. Vidya R, Masià J, Berna G, et al. "Prepectoral implant-based reconstruction — foundational series." Breast J. 2017. DOI: 10.1111/tbj.12810. (Foundational prepectoral technique)
  6. Gschwantler-Kaulich D, et al. "ADM vs synthetic mesh: a randomised comparison." Eur J Surg Oncol. 2016. DOI: 10.1016/j.ejso.2016.02.007. (Randomised ADM vs mesh, ~31% both arms)
  7. Coleman SR, Saboeiro AP. "Fat grafting to the breast revisited: safety and efficacy." Plast Reconstr Surg. 2007;119(3):775–785. DOI: 10.1097/01.prs.0000252001.59152.8a. (Foundational fat grafting technique)
  8. Mazzocchi M, et al. "Bovine pericardium acellular matrix (ExaShape) in implant-based breast reconstruction." Plast Reconstr Regen Surg (PRRS). 2022. DOI: 10.57604/PRRS-064. (Early ExaShape series, n=21 — 1 implant loss)
Educational use only. This page summarises published literature for information and education. It is not clinical advice, not a promotional performance claim for any device, and not a substitute for the relevant Instructions for Use or a qualified clinician's judgement. Figures are drawn from separate studies with differing methods and are indicative, not head-to-head. Reviewed by Advanced Biomedical Concept Medical Team; last reviewed 2026-07-21.

Advanced Biomedical Concept · Clinical Evidence

See the Full Evidence

Request the complete clinical dossier for ExaShape and EXAFAT, or speak with our team about the evidence behind matrix-supported prepectoral reconstruction.

Request the Dossier Read the Pillar Guide

Questions

Frequently asked questions

Can these outcome figures be compared directly to choose a material?

No. The figures come from separate published studies with different patient cohorts, complication definitions and follow-up periods. They provide indicative context, not a controlled head-to-head comparison. A lower number in one study does not on its own prove one material or technique is superior; material choice should rest on the full evidence, device indications and clinical judgement.

What outcomes does the evidence show for bovine pericardium biological matrix?

Published bovine-pericardium series report encouraging early outcomes — for example a prepectoral direct-to-implant cohort with 9.2% major complications (De Vita 2024, n=65) — but the device-specific evidence base is newer and smaller than the large ADM registries and meta-analyses. The honest reading is that the data is indicative and promising rather than yet definitive.

Why does a smaller study sometimes show a higher complication or implant-loss percentage?

With small denominators a single event moves the percentage sharply: one implant loss in 21 patients is 4.8%, whereas the same event across 1,450 procedures would be under 0.1%. Small early series therefore carry wide confidence intervals and should be interpreted with caution alongside larger registry and meta-analytic data.